Similar to existing evidence, we found a higher risk of genital infection associated with SGLT2 inhibitors (primarily dapagliflozin) but no increased risk of UTIs compared to DPP-4 use (Diabetes Research and Clinical Practice)
Diabetes News
Tag: SGLT2 inhibitors
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
All the researches, mentioned in this paper, demonstrating the SGLT2 inhibitors with their novel mechanism and associated benefits on glucose-lowering, renoprotection, body weight, CV safety, etc. have proved to be promising choices either as monotherapy or as combination therapy for patients with DKD (Cardiovascular Diabetology)
Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients
Our meta-analysis based on available RCT data does not support the harm effect of SGLT2 inhibitors on fracture, although future safety monitoring from RCT and real-world data with detailed information on bone health is warranted (Diabetes, Obesity and Metabolism)
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and death (The Lancet Diabetes & Endocrinology)
SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalised a review of SGLT2 inhibitors (a class of type 2 diabetes medicines) and has made recommendations to minimise the risk of diabetic ketoacidosis (EMA)
Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to insulin degludec/liraglutide
Although the effects differ with each individual class of therapy, clinical trials have shown that adding a glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor or sodium-glucose co-transporter-2 inhibitor to insulin regimens can offer a significant reduction in HbA1c without substantially increasing hypoglycaemia risk, or weight (Diabetic Medicine)
Glycosmedia is also available as an App: